{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:37:21Z","timestamp":1770881841423,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T00:00:00Z","timestamp":1701648000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Maroone Cancer Center Hematologic Malignancy Research Fund"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1038\/s41375-023-02100-x","type":"journal-article","created":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T10:03:03Z","timestamp":1701684183000},"page":"435-437","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real world analysis on the determinants of survival in primary plasma cell leukemia in the United States"],"prefix":"10.1038","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2743-674X","authenticated-orcid":false,"given":"Ludovic","family":"Saba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin S.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chieh-Lin","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-2217","authenticated-orcid":false,"given":"Chakra P.","family":"Chaulagain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,4]]},"reference":[{"key":"2100_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-019-0754-x","volume":"21","author":"MT Gundesen","year":"2019","unstructured":"Gundesen MT, Lund T, Moeller HEH, Abildgaard N. Plasma cell leukemia: definition, presentation, and treatment. Curr Oncol Rep. 2019;21:8.","journal-title":"Curr Oncol Rep"},{"key":"2100_CR2","doi-asserted-by":"publisher","first-page":"263485352199938","DOI":"10.1177\/2634853521999389","volume":"14","author":"CP Chaulagain","year":"2021","unstructured":"Chaulagain CP, Diacovo MJ, Van A, Martinez F, Fu CL, Jimenez Jimenez AM, et al. Management of primary plasma cell leukemia remains challenging even in the era of novel agents. Clin Med Insights Blood Disord. 2021;14:2634853521999389.","journal-title":"Clin Med Insights Blood Disord"},{"key":"2100_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/leu.2012.336","volume":"27","author":"C Fern\u00e1ndez de Larrea","year":"2013","unstructured":"Fern\u00e1ndez de Larrea C, Kyle RA, Durie BGM, Ludwig H, Usmani S, Vesole DH, et al. Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group. Leukemia. 2013;27:780\u201391.","journal-title":"Leukemia"},{"key":"2100_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2147\/CLEP.S99463","volume":"8","author":"P Gimsing","year":"2016","unstructured":"Gimsing P, Holmstr\u00f6m MO, Klausen TW, Andersen NF, Gregersen H, Pedersen RS, et al. The Danish National Multiple Myeloma Registry. Clin Epidemiol. 2016;8:583\u20137.","journal-title":"Clin Epidemiol"},{"key":"2100_CR5","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1182\/blood-2014-03-565051","volume":"124","author":"WI Gonsalves","year":"2014","unstructured":"Gonsalves WI, Rajkumar SV, Go RS, Dispenzieri A, Gupta V, Singh PP, et al. Trends in survival of patients with primary plasma cell leukemia: a population-based analysis. Blood. 2014;124:907\u201312.","journal-title":"Blood"},{"key":"2100_CR6","doi-asserted-by":"publisher","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","volume":"116","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724\u201334.","journal-title":"Blood"},{"key":"2100_CR7","doi-asserted-by":"publisher","first-page":"5734","DOI":"10.1002\/cncr.24700","volume":"115","author":"G Ramsingh","year":"2009","unstructured":"Ramsingh G, Mehan P, Luo J, Vij R, Morgensztern D. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer. 2009;115:5734\u20139.","journal-title":"Cancer"},{"key":"2100_CR8","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1038\/s41375-020-0830-0","volume":"34","author":"B Dhakal","year":"2020","unstructured":"Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, et al. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia. 2020;34:3338\u201347.","journal-title":"Leukemia."},{"key":"2100_CR9","doi-asserted-by":"publisher","first-page":"804","DOI":"10.3324\/haematol.2009.013334","volume":"95","author":"MB Drake","year":"2010","unstructured":"Drake MB, Iacobelli S, van Biezen A, Morris C, Apperley JF, Niederwieser D, et al. Primary plasma cell leukemia and autologous stem cell transplantation. Haematologica. 2010;95:804\u20139.","journal-title":"Haematologica"},{"key":"2100_CR10","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1111\/bjh.15092","volume":"180","author":"A Jurczyszyn","year":"2018","unstructured":"Jurczyszyn A, Radocha J, Davila J, Fiala MA, Gozzetti A, Grz\u0105\u015bko N, et al. Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients. Br J Haematol. 2018;180:831\u20139.","journal-title":"Br J Haematol"},{"key":"2100_CR11","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.23600","volume":"89","author":"E Katodritou","year":"2014","unstructured":"Katodritou E, Terpos E, Kelaidi C, Kotsopoulou M, Delimpasi S, Kyrtsonis MC, et al. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: analysis of the Greek myeloma study group. Am J Hematol. 2014;89:145\u201350.","journal-title":"Am J Hematol"},{"key":"2100_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/ejh.13597","volume":"106","author":"IS Sverrisd\u00f3ttir","year":"2021","unstructured":"Sverrisd\u00f3ttir IS, R\u00f6gnvaldsson S, Thorsteinsdottir S, G\u00edslason GK, Aspelund T, Turesson I, et al. Comorbidities in multiple myeloma and implications on survival: A population-based study. Eur J Haematol. 2021;106:774\u201382.","journal-title":"Eur J Haematol"},{"key":"2100_CR13","doi-asserted-by":"publisher","first-page":"106542","DOI":"10.1016\/j.leukres.2021.106542","volume":"104","author":"SS Makhani","year":"2021","unstructured":"Makhani SS, Shively D, Castro G, Rodriguez de la Vega P, Barengo NC. Association of insurance disparities and survival in adults with multiple myeloma: A non-concurrent cohort study. Leuk Res. 2021;104:106542.","journal-title":"Leuk Res"},{"key":"2100_CR14","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387:495\u2013505.","journal-title":"N Engl J Med"},{"key":"2100_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma. N. Engl J Med. 2023;388:1002\u201314.","journal-title":"N. Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02100-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T11:05:32Z","timestamp":1707131132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-023-02100-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,4]]},"references-count":15,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2100"],"URL":"https:\/\/doi.org\/10.1038\/s41375-023-02100-x","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,4]]},"assertion":[{"value":"13 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. The NCDB, a collaboration between the CoC of the American College of Surgeons and the American Cancer Society, provides the de-identified data used here. The CoC\u2019s NCDB and its participating hospitals haven\u2019t verified the data\u2019s statistical validity or the authors\u2019 conclusions.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}